ECSP11010842A - Nuevos derivados de 2-amidotiadiazol - Google Patents

Nuevos derivados de 2-amidotiadiazol

Info

Publication number
ECSP11010842A
ECSP11010842A EC2011010842A ECSP11010842A ECSP11010842A EC SP11010842 A ECSP11010842 A EC SP11010842A EC 2011010842 A EC2011010842 A EC 2011010842A EC SP11010842 A ECSP11010842 A EC SP11010842A EC SP11010842 A ECSP11010842 A EC SP11010842A
Authority
EC
Ecuador
Prior art keywords
group
groups
optionally substituted
alkyl
halogen atoms
Prior art date
Application number
EC2011010842A
Other languages
English (en)
Inventor
Izquierdo Nuria Aguilar
Poveda Pedro Manuel Grima
Cepeda Marta Mir
Martinez Manuel Lopez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of ECSP11010842A publication Critical patent/ECSP11010842A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fórmula (I)Nuevos derivados de 2-amidotiadiazol que tienen la estructura química representada por la fórmula (I) o sales o N-óxidos de los mismos farmacéuticamente aceptablesR1 representa:¢ un grupo heteroarilo que contiene N, bicíclico, de 8 a 10 miembros, opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos hidroxicarbonilo, grupos alquilo C1-4, grupos haloalquilo C1-4, grupos alcoxi C1-4 y grupos cicloalquilo C3-4;¢ un grupo piridilo sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos hidroxi, grupos hidroxicarbonilo, grupos alquilo C1-4, grupos haloalquilo C1-4, grupos alcoxi C1-4, grupos cicloalquilo C3-4 y grupos -NR'R'', donde R' representa un átomo de hidrógeno o un grupo alquilo C1-4 y R'' representa un átomo de hidrógeno o un grupo alquilo C1-4 opcionalmente sustituido con un grupo hidroxi;¢ un grupo piridona sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4 y grupos haloalquilo C1-4; o¢ un grupo de fórmula:donde:" Ra representa un átomo de hidrógeno o un grupo alquilo C1-4," Rb representa un átomo de hidrógeno, átomo de halógeno o grupo alquilo C1-4," Rd representa un átomo de hidrógeno, un grupo alquilo C1-4 o un grupo cicloalquilo C3-4," Rc representa un grupo hidroxi; un grupo alcoxi C1-4 que está opcionalmente sustituido con uno o más sustituyentes seleccionados de grupos hidroxi, grupos alcoxi C1-3, grupos hidroxicarbonilo, grupos alcoxi C1-4 carbonilo y grupos NHR4, donde R4 representa un átomo de hidrógeno; o Rc es un grupo acilo C2-4 o un grupo alquilo C1-4 opcionalmente sustituido con un grupo hidroxicarbonilo, o Rc representa -(CH2)(0-4)-L-R5 donde L representa -C(O)O-, -C(O)NH-, -S(O)2NH-, -NH-, -CONHS(O)2- o un grupo de fórmula:donde n y m independientemente son números enteros de 1 a 2, y R5 representa un átomo de hidrógeno o un grupo alquilo C1-4 opcionalmente sustituido con un grupo hidroxicarbonilo;R2 representa:" un grupo arilo C5-10 monocíclico o bicíclico opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4, grupos alcoxi C1-4 y grupos fenilo, donde el grupo alquilo está opcionalmente sustituido con uno o más átomos de halógeno," un grupo heteroarilo de 5-10 miembros monocíclico o bicíclico que comprende uno o más heteroátomos seleccionados de N, S y O opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno, grupos alquilo C1-4 y alcoxi C1-4, donde el grupo alquilo C1-4 está opcionalmente sustituido con uno o más átomos de halógeno," un grupo dihidrobenzodioxina o un grupo bencilo que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halógeno,yR3 representa:" un grupo alquilo C1-6 lineal o ramificado, cicloalquil C3-6-alquilo C1-4, alcoxi C1-4-alquilo C1-4, un grupo di-alquilamino-alquilo C1-4, o un grupo fenil-alquilo C1-4;con la condición de que cuando Rc representa un grupo metoxi o etoxi, entonces uno de Rb o Rd no puede ser un átomo de hidrógeno;con la condición adicional de que el compuesto de fórmula (I) no es N-metil-N-(5-(6-metilpiridin-3-il)-1,3,4-tiadiazol-2-il)nicotinamida, ni N-metil-N-(5-(6-metilpiridin-3-il)-1,3,4-tiadiazol-2-il)isonicotinamida.
EC2011010842A 2008-10-14 2011-02-21 Nuevos derivados de 2-amidotiadiazol ECSP11010842A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382042A EP2177521A1 (en) 2008-10-14 2008-10-14 New 2-Amidothiadiazole Derivatives

Publications (1)

Publication Number Publication Date
ECSP11010842A true ECSP11010842A (es) 2011-03-31

Family

ID=40386238

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010842A ECSP11010842A (es) 2008-10-14 2011-02-21 Nuevos derivados de 2-amidotiadiazol

Country Status (20)

Country Link
US (1) US20110200557A1 (es)
EP (2) EP2177521A1 (es)
JP (1) JP2012505260A (es)
KR (1) KR20110067034A (es)
CN (1) CN102186847A (es)
AR (1) AR073821A1 (es)
AU (1) AU2009304274A1 (es)
BR (1) BRPI0914371A2 (es)
CA (1) CA2740614A1 (es)
CL (1) CL2011000795A1 (es)
CO (1) CO6321168A2 (es)
EA (1) EA201100612A1 (es)
EC (1) ECSP11010842A (es)
IL (1) IL211290A0 (es)
MX (1) MX2011003692A (es)
PE (1) PE20110420A1 (es)
TW (1) TW201018679A (es)
UY (1) UY32167A (es)
WO (1) WO2010043377A1 (es)
ZA (1) ZA201101236B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6100687B2 (ja) * 2010-08-31 2017-03-22 ダウ アグロサイエンシィズ エルエルシー 農薬組成物
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
CN103502221B (zh) 2011-03-18 2016-03-30 拜耳知识产权有限责任公司 N-(3-氨甲酰基苯基)-1h-吡唑-5-甲酰胺衍生物及其用于防治动物害虫的用途
CN102276554B (zh) * 2011-06-28 2013-10-30 四川大学 4-（（2-氨基-5-巯基-1,3,4-噻二唑）-甲基）-苯甲酰胺衍生物及其制备方法和用途
FR2988000A1 (fr) * 2012-03-16 2013-09-20 Thomas Wandji Composition pharmaceutique active dans la therapie des affections virales humaines et animales
WO2014070978A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
JP6372666B2 (ja) 2012-11-03 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
HRP20220790T1 (hr) 2017-05-04 2022-09-16 Bayer Cropscience Aktiengesellschaft Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
RU2672887C1 (ru) * 2018-03-13 2018-11-20 Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ (АО "ВНЦ БАВ") N-(5-Этил-1,3,4-тиадиазол-2-ил)-2-пропилпентанамид, обладающий противоэпилептической и обезболивающей активностями
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2303792A (en) 1992-06-23 1994-01-24 Motorola, Inc. Multi-modulation scheme compatible radio
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
RU2003133750A (ru) * 2001-04-19 2005-05-10 Байер АГ (DE) Арилсульфонамиды в качестве антивирусных агентов
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
EP1484057A1 (en) 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
AU2004271804B2 (en) 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
JP2009528274A (ja) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007143081A2 (en) 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
HRP20121034T1 (hr) 2006-08-17 2013-01-31 University Of Chicago Lijeäśenje upalnih bolesti
PL2069335T3 (pl) * 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
WO2008091967A1 (en) * 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds

Also Published As

Publication number Publication date
CO6321168A2 (es) 2011-09-20
EP2334670A1 (en) 2011-06-22
AU2009304274A1 (en) 2010-04-22
UY32167A (es) 2010-01-05
JP2012505260A (ja) 2012-03-01
PE20110420A1 (es) 2011-07-01
MX2011003692A (es) 2011-04-27
WO2010043377A1 (en) 2010-04-22
KR20110067034A (ko) 2011-06-20
IL211290A0 (en) 2011-04-28
EP2177521A1 (en) 2010-04-21
US20110200557A1 (en) 2011-08-18
EA201100612A1 (ru) 2011-12-30
AR073821A1 (es) 2010-12-01
BRPI0914371A2 (pt) 2019-09-24
CN102186847A (zh) 2011-09-14
ZA201101236B (en) 2011-09-28
CA2740614A1 (en) 2010-04-22
CL2011000795A1 (es) 2011-08-19
TW201018679A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
ECSP11010842A (es) Nuevos derivados de 2-amidotiadiazol
ECSP11010844A (es) Nuevos derivados de 2-amidotiadiazol
ECSP11011083A (es) Nuevos compuestos
CO6251241A2 (es) Compuestos de prolina modificados con actividad anti-vhc
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
JO2791B1 (en) Acid secretion inhibitor
AR057244A1 (es) Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes.
AR073136A1 (es) Compuestos de pirrol
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
NI200900037A (es) Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica.
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
PH12015501813A1 (en) Monocyclic pyridine derivative
ECSP088479A (es) Derivados de oxadiazol
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
ECSP13012405A (es) Compuestos heterocíclicos fusionados
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
ES2682398T3 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
EA201170093A1 (ru) Замещенные n-оксидпиразиновые производные
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
AR066605A1 (es) Derivados de heteroarilamida pirimidona